Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncogenic Corepressor Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BCOR drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BCOR Recombinant Protein (BCL6-Binding Domain) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View BCOR Products |
| Gene Delivery | BCOR Promise-ORF / Lentivirus Full-length ORF (WT and ITD Mutants) for stable cell lines. |
View BCOR Products |
| Benchmark Ab | Anti-BCOR Recombinant Antibody Recombinant positive control for IP, Western Blot, and ChIP. |
View BCOR Products |
| Validator | BCOR siRNA Set For knockdown verification in functional assays. |
View BCOR Products |
| Related Target A | BCL6 Direct interaction partner; target of BCL6-BCOR co-repressor complex inhibitors. |
View BCL6 Products |
| Related Target B | PCGF1 Core component of the non-canonical PRC1.6 complex containing BCOR. |
View PCGF1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Disrupting BCL6-BCOR PPI | High-purity BCOR peptide/domain fusions strictly verified by mass spectrometry for HTRF/FP assays. |
| Modeling BCOR-ITD in oncogenesis | High-titer Lentivirus expressing WT or mutant BCOR (ITD) for robust stable cell line generation. |
| Lack of Controls | Sequence-verified Recombinant Benchmark Antibodies included. |
| False Positives | Validated siRNA sets included for target specificity and knockdown verification. |
Live BCOR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BCOR therapeutics is intensifying, with major players shifting focus from traditional transcription factor inhibition to targeted protein degradation (PROTACs) and disruptors of the BCL6-BCOR interaction interface. As first-generation therapies reach the clinic, the next wave of R&D is targeting BCOR-internal tandem duplications (ITD) and fusion-positive pediatric sarcomas.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Consortia, Biotech Startups | DLBCL, Solid Tumors | BCL6-BCOR Interaction Assay (Need high-purity recombinant BCOR domains) |
| PROTACs / Degraders | Preclinical Biotechs | Lymphoma, CCSK | Target Degradation Verification (Need validated siRNA and high-titer Lentivirus) |
| Combination Therapies (w/ HDACi) | Clinical Investigators | AML, MDS, Sarcomas | Cell-based Epigenetic Assays (Need stable cell lines via Lentivirus delivery) |